Is IPCA Laboratories (IPCALAB) overvalued or fairly valued?

MarketChacha shows IPCA Laboratories's valuation in context — a forward P/E of about 27.2, a price-to-book of about 5.6 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is IPCA Laboratories's revenue?

IPCA Laboratories reported revenue of ₹9,646 Cr for FY2026, with net profit of ₹1,141 Cr, per official filings.

What is the share price of IPCA Laboratories (IPCALAB)?

IPCA Laboratories last traded at ₹1,788.50 (-2.7% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

IPCA Laboratories

IPCALAB · NSE · Pharma · India

₹1,788.50-2.7%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 10:00 AM

Snapshot

TickerIPCALAB

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees17,210

HeadquartersMumbai, India

Market cap₹45,375 Cr

P/B5.6

Volume1.93L

Websitewww.ipca.com

Filings tracked0

About IPCA Laboratories

Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.

Profile as reported by Yahoo Finance.

Who owns it

Promoters45.1%
Institutions45.0%
Public & other10.0%

79 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend8.7% → 11.8%

Margin has expanded by about 3.1 points — the business is getting more profitable.

Growth qualityrev 18% · PAT 31%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹2,776 Cr

Next fiscal year

Rev ₹12,008 Cr · EPS 65.66

Est. earnings growth +18.9%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

₹1,251.6052-wk range₹1,944.90

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Market cap

₹45,375 Cr

Day change

-2.7%

Fwd P/E

27.2

P/B

5.6

Div yield

0.33%

Beta

0.05

Revenue (FY2026)

₹9,646 Cr

Net margin

11.8%

Revenue CAGR (3y)

+18.4%

Profit CAGR (3y)

+31.2%

Net profit (FY2026)

₹1,141 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about IPCALAB

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹9,646 Cr	₹1,141 Cr	11.8%
FY2025	₹8,940 Cr	₹738 Cr	8.3%
FY2024	₹7,705 Cr	₹547 Cr	7.1%
FY2023	₹5,815 Cr	₹506 Cr	8.7%

Quarterly

Period	Revenue	Net profit	Net margin
2026Q1	₹2,388 Cr	₹299 Cr	12.5%
2025Q4	₹2,393 Cr	₹326 Cr	13.6%
2025Q3	₹2,557 Cr	₹283 Cr	11.1%
2025Q2	₹2,309 Cr	₹233 Cr	10.1%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.